PRASUGREL vs TICAGRELOR

Compare PRASUGREL (Prasugrel) and TICAGRELOR (Ticagrelor) — clinical data, side effects, and patient experiences.

PRASUGREL

Prasugrel, Effient · Antiplatelet

How it works

12.1 Mechanism of Action Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP recep...

Approved for

nonfatal myocardial infarction (MI)

or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI

with no difference on strokes and little difference on CV death [see Clinical Studies (14) ] .

OralTablet

TICAGRELOR

Ticagrelor, Brilinta · Antiplatelet

How it works

12.1 Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticag...

Approved for

1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death

myocardial infarction (MI)

and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS

myocardial infarction (MI)

OralTablet

Quick Comparison

PRASUGRELTICAGRELOR

Drug Class

Antiplatelet

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PRASUGREL

Chest Pain

1-10%

Shortness of Breath

1-10%

Fatigue

1-10%

Nausea

1-10%

Dizziness

1-10%

Drug Not Working

1-10%

Headache

0.1-1%

TICAGRELOR

Shortness of Breath

>10%

Fatigue

1-10%

Chest Pain

1-10%

Dizziness

1-10%

Weakness

0.1-1%

General Unwellness

0.1-1%

Nausea

0.1-1%

Drug Not Working

0.1-1%

FDA Warnings

PRASUGREL

5 WARNINGS AND PRECAUTIONS CABG-related bleeding: Risk increases in patients receiving prasugrel who undergo CABG (5
Discontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death (5
1 General Risk of Bleeding Thienopyridines, including prasugrel, increase the risk of bleeding
The bleeding risk is highest initially, as shown in Figure 1 (events through 450 days; inset shows events through 7 days)

TICAGRELOR

5 WARNINGS AND PRECAUTIONS • Dyspnea was reported more frequently with ticagrelor than with control agents in clinical trials
1 Risk of Bleeding Drugs that inhibit platelet function including ticagrelor increase the risk of bleeding [see Warnings and Precautions ( 5
2 Discontinuation of Ticagrelor Tablets in Patients Treated for Coronary Artery Disease Discontinuation of ticagrelor tablets will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease
When possible, interrupt therapy with ticagrelor tablets for five days prior to surgery that has a major risk of bleeding

Clinical Trial Data

No head-to-head clinical studies found for PRASUGREL vs TICAGRELOR.

PRASUGREL vs TICAGRELOR: What You Should Know

Key Differences

Both PRASUGREL and TICAGRELOR belong to the Antiplatelet class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

PRASUGREL carries 4 FDA warnings. TICAGRELOR carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

CLOPIDOGREL BISULFATE vs TICAGRELOR→CLOPIDOGREL BISULFATE vs PRASUGREL→CLOPIDOGREL vs TICAGRELOR→CLOPIDOGREL vs PRASUGREL→APIXABAN vs TICAGRELOR→APIXABAN vs PRASUGREL→

Loading comparison data...

PRASUGREL vs TICAGRELOR

Compare PRASUGREL (Prasugrel) and TICAGRELOR (Ticagrelor) — clinical data, side effects, and patient experiences.

PRASUGREL

Prasugrel, Effient · Antiplatelet

How it works

12.1 Mechanism of Action Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP recep...

Approved for

nonfatal myocardial infarction (MI)

or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI

with no difference on strokes and little difference on CV death [see Clinical Studies (14) ] .

OralTablet

TICAGRELOR

Ticagrelor, Brilinta · Antiplatelet

How it works

12.1 Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticag...

Approved for

1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death

myocardial infarction (MI)

and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS

myocardial infarction (MI)

OralTablet

Quick Comparison

PRASUGRELTICAGRELOR

Drug Class

Antiplatelet

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

PRASUGREL

Chest Pain

1-10%

Shortness of Breath

1-10%

Fatigue

1-10%

Nausea

1-10%

Dizziness

1-10%

Drug Not Working

1-10%

Headache

0.1-1%

TICAGRELOR

Shortness of Breath

>10%

Fatigue

1-10%

Chest Pain

1-10%

Dizziness

1-10%

Weakness

0.1-1%

General Unwellness

0.1-1%

Nausea

0.1-1%

Drug Not Working

0.1-1%

FDA Warnings

PRASUGREL

5 WARNINGS AND PRECAUTIONS CABG-related bleeding: Risk increases in patients receiving prasugrel who undergo CABG (5
Discontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death (5
1 General Risk of Bleeding Thienopyridines, including prasugrel, increase the risk of bleeding
The bleeding risk is highest initially, as shown in Figure 1 (events through 450 days; inset shows events through 7 days)

TICAGRELOR

5 WARNINGS AND PRECAUTIONS • Dyspnea was reported more frequently with ticagrelor than with control agents in clinical trials
1 Risk of Bleeding Drugs that inhibit platelet function including ticagrelor increase the risk of bleeding [see Warnings and Precautions ( 5
2 Discontinuation of Ticagrelor Tablets in Patients Treated for Coronary Artery Disease Discontinuation of ticagrelor tablets will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease
When possible, interrupt therapy with ticagrelor tablets for five days prior to surgery that has a major risk of bleeding

Clinical Trial Data

No head-to-head clinical studies found for PRASUGREL vs TICAGRELOR.

PRASUGREL vs TICAGRELOR: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.